ClinicalTrials.gg
RecruitingNCT07074756Updated Aug 10, 2026

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

An interventional study of Chemotherapy and Computed Tomography in Glioma, Recurrent Glioma and Recurrent Glioblastoma, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Primary conditionGlioblastomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Glioblastoma by Mayo Clinic — 12 open to participants now, 16 under way, 1 of them phase 3. Glioblastoma · Mayo Clinic.

Planned enrollment
2nd of 23
202 · median 36
Started
2025
with 3 others
No phase
5 of 23
4 open now
Primary completion
2028-08
later than 10 of 15 live
Registered
15th of 23
by date

Among the 23 studies in Glioblastoma by Mayo Clinic, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2025, is one of 5 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 15th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

12 of the 23 studies in Glioblastoma by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Glioblastoma by Mayo Clinic, or all of them as a file.
02

Study summary

This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the feasibility of the remote chemotherapy management and patient monitoring platform glioma home-based sequential therapy (GHoST) protocol among patients with glioma undergoing systemic therapy.

II. Determine the efficacy, as measured by the 4-month progression free survival (PFS) rate, of propranolol and imipramine, when used in combination with bevacizumab for the treatment of recurrent glioblastoma. (Subprotocol 1: PRIME)

SECONDARY OBJECTIVES:

I. Evaluate compliance, adherence, and feasibility in terms of the adherence to systemic therapy monitored remotely.

II. Determine progression free survival (PFS) for each therapeutic evaluated for newly diagnosed or recurrent glioma, stratified by tumor type.

III. Determine objective response rate (ORR) for each therapeutic evaluated for newly diagnosed or recurrent glioma, stratified by tumor type.

IV. Assess the safety and tolerability of remote chemotherapy management and patient monitoring among patients with glioma undergoing systemic therapy.

V. Determine overall survival (OS) for each therapeutic evaluated for recurrent glioblastoma when used in combination with bevacizumab. (Subprotocol 1: PRIME) VI. Determine objective response rate (ORR) for each therapeutic evaluated for recurrent glioblastoma when used in combination with bevacizumab. (Subprotocol 1: PRIME) VII. Assess the safety and tolerability for each therapeutic evaluated for recurrent glioblastoma when used in combination with bevacizumab. (Subprotocol 1: PRIME)

EXPLORATORY OBJECTIVES:

I. Assess the acceptance or satisfaction of patients with the remote monitoring in this trial and how these may differ between newly diagnosed and recurrent glioma.

II. Investigate PFS based on therapeutic sequence administered. III. Explore potential differences in compliance, adherence, and satisfaction measures and how they may correspond to health disparities and social determinants of health.

IV. Compare access to neuro-oncology care at Mayo Clinic among patients with low socioeconomic status assessed based on the Mayo Clinic Housing-Based Socioeconomic Status (HOUSES) Index during the two years following study activation compared to historical utilization data.

V. Compare access to neuro-oncology care at Mayo Clinic among patients with increased distance from academic centers assessed by geospatial index during the two years following study activation compared to historical utilization data.

OUTLINE:

GHoST MASTER PROTOCOL: Patients receive access to the remote chemotherapy management and patient monitoring platform to watch educational videos, report when medication is taken or missed, and report any symptoms related to cancer or medication side effects on study. Patients also receive standard of care chemotherapy as assigned by their treating physician as part of the platform on study. Upon completion of standard of care chemotherapy, if there is no disease progression, patients transition to surveillance for up to 1 year. Patients who experience disease progression during treatment or surveillance may rejoin the platform and/or be assigned by their treating physician to a different chemotherapy agent as part of the platform. Patients also undergo magnetic resonance imaging (MRI) or computed tomography (CT) throughout the study.

SUBPROTOCOL 1 - PRIME: Patients with recurrent glioblastoma receiving bevacizumab on the GHoST Master Protocol as assigned by their treating physician are randomized to 1 of 2 groups.

GROUP A: Patients receive propranolol orally (PO) twice daily (BID) and standard of care (SOC) bevacizumab intravenously (IV) every 3 weeks of each cycle. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the study.

GROUP B: Patients receive imipramine PO once daily (QD) and SOC bevacizumab IV every 3 weeks of each cycle. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the study.

03

Conditions studied

  • Glioma
  • Recurrent Glioma
  • Recurrent Glioblastoma

Browse trials for

04

In context

Glioblastoma Reclassified

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 202 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months.

    • NOTE: Patient may be enrolled following completion of surgery and/or radiation therapy for newly diagnosed or recurrent tumor.
    • NOTE: Any number of prior recurrences is permitted
  • (ECOG) performance status of 0, 1, or 2, AND performance status (KPS) of ≥ 60
  • Expected survival ≥ 6 months in the opinion of treatment team
  • Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations
  • Negative pregnancy test ≤ 8 days prior to registration for persons of only

    • Exception: Not required if patient is already on treatment. May be obtained prior to next treatment as needed per clinical care
  • Provide written
  • Ability to complete assessments and questionnaires by themselves or with assistance
  • SUBSTUDY 1: Enrolled in GHoST Master Protocol per eligibility criteria of the master study and clinically appropriate to proceed with bevacizumab treatment at the discretion of the treating physician
  • SUBSTUDY 1: Diagnosis of recurrent glioblastoma and intention to treat with bevacizumab

    • NOTE: Any number of prior recurrences is permitted
    • NOTE: Prior limited use of bevacizumab for radiation necrosis/treatment related edema is permitted. Prior use should not exceed four infusions with the last dose administered ≥ 4 weeks prior to enrollment in this substudy
  • SUBSTUDY 1: Willing and able to adhere to the substudy for the duration of the substudy including undergoing treatment, and attending scheduled visits, and examinations
  • SUBSTUDY 1: Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only
  • SUBSTUDY 1: Provide written informed consent
  • SUBSTUDY 1: Ability to complete assessments and questionnaires by themselves or with assistance

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing, imprisoned, or lacking capacity for understanding
  • Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
  • SUBSTUDY 1: Pregnant or nursing, imprisoned, or lacking capacity for understanding
  • SUBSTUDY 1: Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    GHoST Master Protocol (remote chemotherapy management)

    Patients receive access to the remote chemotherapy management and patient monitoring platform to watch educational videos, report when medication is taken or missed, and report any symptoms related to cancer or medication side effects on study. Patients also receive standard of care chemotherapy as assigned by their treating physician as part of the platform on study. Upon completion of standard of care chemotherapy, if there is no disease progression, patients transition to surveillance for up to 1 year. Patients who experience disease progression during treatment or surveillance may rejoin the platform and/or be assigned by their treating physician to a different chemotherapy agent as part of the platform. Patients also undergo MRI or CT throughout the study.

    Drug: Chemotherapy · Procedure: Computed Tomography · Other: Internet-Based Intervention · Procedure: Magnetic Resonance Imaging · Procedure: Neurologic Examination · Other: Questionnaire Administration · Behavioral: Surveillance

  • Experimental
    Subprotocol 1 Group A (propranolol, bevacizumab)

    Patients receive propranolol PO BID and SOC bevacizumab IV every 3 weeks of each cycle. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the study.

    Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Neurologic Examination · Other: Questionnaire Administration · Drug: Propranolol · Drug: Imipramine

  • Experimental
    Subprotocol 1 Group B (imipramine, bevacizumab)

    Patients receive imipramine PO QD and SOC bevacizumab IV every 3 weeks of each cycle. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the study.

    Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Neurologic Examination · Other: Questionnaire Administration · Drug: Imipramine · Drug: Bevacizumab

Interventions

  • DrugChemotherapy

    Receive standard of care chemotherapy

    Also known as: Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • OtherInternet-Based Intervention

    Receive access to the remote chemotherapy management and patient monitoring platform

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureNeurologic Examination

    Ancillary studies

    Also known as: Nervous System Examination, Neurological Assessment, neurological exam, Neurological Examination, NVEXAM

  • OtherQuestionnaire Administration

    Ancillary studies

  • BehavioralSurveillance

    Undergo surveillance

    Also known as: Epidemiology / Surveillance

  • Given PO

    Also known as: 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol, 525-66-6

  • Given PO

    Also known as: 50-49-7, 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-

  • Given IV

    Also known as: ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avegra, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Equidacent, CTP16, CT P16, CT-P16, FKB 238, FKB238, FKB-238, HD204, IBI 305, IBI-305, IBI305, Jobevne, Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev, SCT501, SIBP 04, SIBP-04, SIBP04, MB 02, MB-02, MB02

07

What researchers measure

Primary outcomes

  1. Feasibility - completion of study visits

    Feasibility will be assessed by the number of study visits completed vs. not. Will consider this to be feasible in this patient population if the true compliance rate is at least 60%. Compliance here is defined as completion of at least 4 disease assessment timepoints in the first 6 months on study (i.e. 26 ± 2 weeks). These assessment timepoints will include the baseline assessment and can include assessments after 2 cycles of therapy, after 4 cycles of therapy, after 6 cycles of therapy, dependent on the treatment-specific schedules.

    Time frame: At baseline and the set of study-specific visits through 6 months (i.e., 26 weeks ± 2 weeks)

  2. 4-month progression-free survival (PFS) rate (Subprotocol 1)

    Defined as the number of patients who are alive and progression-free at least 4 months after beginning study therapy. A point estimate will be generated for 4-month PFS rate.

    Time frame: Up to 4 months after beginning study therapy

Secondary outcomes

  1. Acceptance of and satisfaction of patients with the remote monitoring

    Will be assessed with an electronic Assessment of Acceptance and Satisfaction survey sent to participants at study assessment timepoints. The satisfaction survey consists of a single question answered on a 5-point scale: very positive, somewhat positive, neutral, somewhat negative, very negative.

    Time frame: Up to 3 years

  2. Adherence to study therapeutics

    Will be assessed through remote monitoring application. Here, adherence is defined as taking at least 80% of the prescribed doses, for all therapies other than lomustine. For lomustine, adherence is defined as receiving all prescribed infusions.

    Time frame: Up to 3 years

  3. Feasibility of remote systemic therapy assessments

    Will be assessed through completion of visits as scheduled, where laboratory and imaging assessed for the visits are scheduled and completed prior to telehealth visits. Feasibility will be defined as having necessary pre-visit testing completed and delivered for clinician review prior to the visit as well as completion of the visit at the intended scheduled time for 60% of the visits.

    Time frame: Up to 3 years

  4. Progression free survival (PFS) for each therapeutic treatment diagnosed and recurrent glioma

    Will be assessed for each treatment evaluated. PFS is defined as the time from enrollment to disease progression or death, whichever occurs first.

    Time frame: At 6 months

  5. Objective response rate

    Objective response rate for each therapeutic for newly diagnosed and recurrent glioma will be assessed.

    Time frame: Up to 3 years

  6. Incidence of adverse events

    Will be assessed by type along with grade and perceived attribution to study agent based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.

    Time frame: Up to 3 years

  7. Safety of the overall platform

    Will be assessed by acute care utilization days (defined as emergency department evaluations and inpatient days) for participants on the platform compared to historical clinical data.

    Time frame: Up to 3 years

  8. Overall survival (OS) from initiation of study treatment (Subprotocol 1)

    Defined as the time from initiation of study treatment and survival time from initial diagnosis.

    Time frame: Up to 3 years

  9. Objective response rate (ORR) (Subprotocol 1)

    Defined as the time from initiation of study treatment and survival time from initial diagnosis. Will be assessed per Response Assessment in Neuro-Oncology (RANO) Criteria 2.0

    Time frame: Up to 3 years

  10. Incidence of adverse events (Subprotocol 1)

    Will be assessed by type along with grade and perceived attribution to study agent based on NCI CTCAE version 5.

    Time frame: Up to 3 years

08

Study locations

2 of 2 sites recruiting
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2028, 35 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 35 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 20, 2025
StartActual
Sep 12, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07074756
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Sep 12, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Cancer Center Clinical Trials
Contact
507-293-6386
Ugur T. Sener, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propranolol · Imipramine · Bevacizumab

Start the discussion